Abstract | INTRODUCTION: METHODS: Fifteen patients with lung adenocarcinoma harboring the EGFR mutation were administered 250 mg of gefitinib daily. Blood samples were collected prior to the first administration of gefitinib and after 1, 4, 6, 8, and 24 h. Plasma concentrations of gefitinib were measured via liquid chromatography mass spectrometry, and the peak plasma concentration(Cmax)and area under the plasma concentration time curve from 0 to 24 h(AUC 0-24)of gefitinib were determined. The correlations between these pharmacokinetic variables and the objective responses, including progression-free survival(PFS)and overall survival(OS), were retrospectively analyzed. RESULTS: The Cmax of gefitinib in patients with a partial response(PR)was significantly lower than that of patients with stable disease(SD)(median Cmax: 278 vs 588 ng/mL, p<0.05 ). However, the Cmax of gefitinib did not correlate with longer PFS. Conversely, a significant negative correlation was found between the AUC 0-24 of gefitinib and longer survival(r=-0.545, p<0.05 ). CONCLUSIONS:
|
Authors | Satoshi Hirano, Kazumi Sano, Yuichiro Takeda, Satoru Ishii, Go Naka, Motoyasu Iikura, Shinyu Izumi, Masayuki Hojo, Haruhito Sugiyama, Nobuyuki Kobayashi, Koichiro Kudo |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 39
Issue 10
Pg. 1501-6
(Oct 2012)
ISSN: 0385-0684 [Print] Japan |
PMID | 23064060
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Quinazolines
- EGFR protein, human
- ErbB Receptors
- Gefitinib
|
Topics |
- Adenocarcinoma
(drug therapy, genetics)
- Adenocarcinoma of Lung
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(blood, therapeutic use)
- ErbB Receptors
(genetics)
- Female
- Gefitinib
- Humans
- Lung Neoplasms
(drug therapy, genetics)
- Male
- Middle Aged
- Mutation
- Quinazolines
(blood, therapeutic use)
- Retrospective Studies
|